Q1 2025 Ocugen Inc Earnings Call Transcript

May 9, 2025 / 12:30 PM GMT

Release Date Price: MXN15.2

Transcript 8-K10-Q

Key Points

Positve

Ocugen Inc (OCGN) is advancing its gene therapy platforms with plans to file three biologics license applications/market authorization applications in the next three years.
The company has achieved positive clinical data for its modified gene therapy approach, demonstrating long-term safety and efficacy.
Ocugen Inc (OCGN) has aligned with the FDA for a confirmatory trial, potentially accelerating timelines and reducing costs.
The company has completed dosing ahead of schedule in a Phase 2 trial for geographic atrophy, with plans to initiate a Phase 3 trial in 2026.
Ocugen Inc (OCGN) has received eligibility from the EMA to submit its MAA via a centralized procedure, marking a significant milestone.

Negative

Research and development expenses increased to $9.5 million from $6.8 million year-over-year, indicating rising costs.
The company reported a net loss of $15.3 million for the quarter, up from $11.9 million in the previous year.
Cash and restricted cash decreased significantly from $58.8 million to $38.1 million, raising concerns about cash runway.
Ocugen Inc (OCGN) is dependent on strategic partnerships and funding for future trials, which may pose financial risks.
The company faces uncertainties related to regulatory approvals and market acceptance of its gene therapy products.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

OCGN.OQ - Ocugen Inc
Q1 2025 Ocugen Inc Earnings Call
May 09, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to Oxygen's first quarter 2025 financial results and business update. Please note that this call is being recorded at this time. All participant lines are in listen-only mode. Following the speaker's commentary, there will be a question and answer session. I will now turn the call over to Tiffany Hamilton, Oxygen's head of corporate communications. You may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and good morning everyone. Joining me on today's call and webcast is Doctor Shankar Musinari, Oxygen's Chairman, CEO and co-founder, who will

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.